Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Conferences | Events

New Application Note: COVID-19 agent molnupiravir

publication date: Sep 20, 2022
 | 
author/source: YMC Europe GmbH

new-application-note-covid19-agent-molnupiravir

 

Molnupiravir (Lagevrio®) is an antiviral medication to treat mild to medium COVID-19 infection.

Molnupiravir is actually a prodrug of the active substrate N4-hydroxycytidine (NHC), a synthetic ribonucleoside analogue. The treatment leads to the introduction of copying errors during viral RNA replication and by this inhibits the viral reproduction.
 
This new Application Note demonstrates how molnupiravir and its active agent β-d-N4-hydroxycytidine can be separated by using a YMC-Triart C18 UHPLC column and a MS compatible mobile phase at pH 4.3 and relatively mild temperature of 40°C.


 

View Application Note

Recent news from YMC

 


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

Today's Picks

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners